BioXcel Therapeutics to Report Second Quarter 2021 Financial Results on August 10, 2021
BioXcel Therapeutics, Inc. (BTAI) announced the release of its second quarter 2021 financial results scheduled for August 10, 2021, before U.S. market opening. A conference call will follow at 8:30 AM EDT to discuss the results and provide a business update. The company focuses on utilizing artificial intelligence to develop innovative treatments in neuroscience and immuno-oncology, with notable clinical advancements in BXCL501 and BXCL701, aimed at addressing agitation and aggressive prostate cancer, respectively.
- BioXcel is advancing its clinical programs BXCL501 and BXCL701 targeting significant medical needs.
- The innovative use of AI is positioning the company well within the biopharmaceutical space.
- No specific financial metrics or guidance were provided in the PR.
NEW HAVEN, Conn., July 28, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced it will release its second quarter 2021 financial results on Tuesday, August 10, 2021 before the open of the U.S. financial markets. BioXcel’s management team will also host a conference call and webcast at 8:30 AM EDT to discuss the Company’s financial results and to provide a general business update.
| Conference Call & Webcast Details | |
| Date/Time: Domestic: International: | Tuesday, August 10, 2021 at 8:30 AM Eastern Time 877-407-2985 201-378-4915 |
The webcast and the accompanying materials will be accessible* under "Events" on the News & Media page of the Company's website at www.bioxceltherapeutics.com.
| Replay | |
| Domestic: International: Conference ID: | 877-660-6853 201-612-7415 13721977 |
*Replay available through at least August 24, 2021.
BioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. BioXcel's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BioXcel's two most advanced clinical development programs are BXCL501, an investigational, proprietary, orally dissolving thin film formulation of dexmedetomidine for the treatment of agitation and opioid withdrawal symptoms, and BXCL701, an investigational, orally administered, systemic innate immunity activator in development for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. For more information, please visit www.bioxceltherapeutics.com.
Source: BioXcel Therapeutics, Inc.
FAQ
When will BioXcel Therapeutics release its second quarter 2021 financial results?
What are BioXcel's clinical development programs?
What time is the BioXcel conference call for its financial results?
How can I access the BioXcel Therapeutics financial results webcast?
